JTC 2016

JTC2016 (closed)

Heart failure


Facts and figures

Funded projects

Title

Coordinator

Partner (Countries)

Summary (short)

ACM-HF 
Non myocyte interplay as a novel platform for mechanistic insights and therapeutic approaches in ACM heart failure

 Giulio Pompilio, Centro Cardiologico Monzino-IRCCS, Milan, Italy

Germany, France, Spain, Netherlands, Slovenia 

 Heart failure and life-threatening arrhythmias can be indicative of Arrhythmogenic Cardiomyopathy (ACM). In order to test potential therapeutics, this project exploits an innovative patient-derived cell model.
read more 

Cardio-Oncology
Early detection and prevention of cardiac dysfunction and heart failure induced by cancer chemotherapeutics

Canan Nebigil, CNRS, University of Strasbourg, Strasbourg, France

France, Germany, Italy, Taiwan, Netherlands, Turkey

Anticancer treatments such as chemotherapy can cause heart failure. Minimising these harmful effects is the goal of the Cardio-Oncology project.
read more

Cardiopro
Mechanisms of regenerative cardiomyocyte proliferation

Jeroen Bakkers, Hubrecht Institute, Utrecht, Netherlands

Germany, Israel, Italy

This project examines why zebrafish naturally regenerate cardiomyocytes while mice do not. Finding the difference might contribute to developing regenerative medicine strategies for humans with ischemic heart disease.
read more

CLARIFY
Communication between cardiomyocytes and innate immune cells in failing hearts

Eva van Rooij, Hubrecht Institute, Utrecht, Netherlands

Germany, France

After myocardial damage the immune system plays an important part in cellular regenerative responses. CLARIFY investigates the communication between cardiac myocytes, cardiac stem cells and innate immune cells during ischemic heart failure.
read more

DETECTIN-HF
Determining the role of clinical and epigenetic risk markers in dilated cardiomyopathies and heart failure

Hugo A. Katus, University Hospital Heidelberg, Heidelberg, Germany

Estonia, France, Poland, Netherlands

Up to half of the cases of dilated cardiomyopathy can be explained by genetic predisposition. Exploring the precise mechanisms leading to these variations is what this project aims at.
read more

EXPERT
Exploring new pathways in age-related heart diseases

Thomas Thum, Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover, Germany

Netherlands, Italy, Spain, France, Romania

EXPERT will identify pathways of age-related heart failure, and explore noncoding
RNA (ncRNA)-mediated regulatory pathways of the human genome.
read more

FAT4HEART
Heart Failure Rescue by Nutritional Approaches: relevance of mitochondrial substrate utilization

Borja Ibanez, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain

Italy, France

The project explores the potential of a high-fat diet as a therapy for dilated cardiomyopathy.
read more

GENPROVIC
Gene Profiling Test for Identification of Treatable Patients with Acute and Chronic Heart Failure

Heinz-Peter Schultheiss, Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany

Germany, Italy, Spain

GENPROVIC seeks to establish a gene profile biomarker test in order to diagnose patients with virus-induced heart diseases.
read more

LIPCAR-HF
A prognostic marker of heart failure with impaired ejection fraction

Florence Pinet, Inserm1167, Institut Pasteur de Lille, University of Lille, Lille, Florence, France

Germany, Spain, Italy, Poland

The objective of this proposal is the development of the long noncoding RNA LIPCAR as a new
diagnostic and prognostic marker for heart failure (HF) patients.
read more

LYMIT-DIS
Targeted LYmphatic and MIcrovessel Treatments in metabolic-DISease HFpEF

Ebba Brakenhielm, INSERM, Rouen Institute for Research and Innovation in Biomedicine, France

The Netherlands, Poland, Belgium, Spain

Heart Failure with preserved Ejection Fraction (HFpEF) is one of the most prevalent kinds of heart disease. LYMIT-DIS examines the mechanisms involved in the cardiac diastolic dysfunction in HFpEF.
read more

MacroERA
Non-coding RNAs in cardiac macrophages and their role in heart failure

Stefan Engelhardt, Technische Universität München, Munich, Germany

Netherlands, Belgium

The MacroERA project analyses the microRNA portfolio of macrophages and their role in heart failure progression.
read more

MINOTAUR
Metabolic Therapy for Managing Diastolic Heart Failure

Simon Sedej, Medical University of Graz, Graz, Austria

Germany, Portugal, France,
Spain, Switzerland

The consortium tests whether caloric restriction mimetics prevent the development of diastolic dysfunction.
read more

PDE4Heart
Gene therapy with phosphodiesterases to treat heart failure

Rodolphe Fischmeister, INSERM and University Paris-Sud, Paris, France

Germany, Norway, Italy

Researchers test a new gene therapy to prevent or reverse heart failure.
read more

Variation
Novel RNA based therapies for treatment-resistant forms of severe cardiomyopathy caused by LMNA mutations

Yigal Pinto, University of Amsterdam, Amsterdam, Netherlands

France, Israel, Germany

A mutation in Lamin A/C can lead to treatment-resistant forms of severe cardiomyopathy. VARIATION explores novel RNA based therapies targeting the mutated allele.
read more